Chronic kidney disease tracking and SGLT2i effectiveness study
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how well a simple urine test can track chronic kidney disease (CKD) and whether SGLT2 inhibitors (a type of diabetes medicine also used for kidney protection) work in real life. It might help find better ways to manage your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of chronic kidney disease (CKD) at stage 2, 3, or 4 (not stage 5 or end-stage).
- Your doctor expects you to live at least another 12 months.
- Your medical records must have the needed lab results and health information.
- If you take SGLT2 inhibitors, you must not be allergic or unable to take them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin, a daily pill, is safe and helps children ages 2–17 with chronic kidney disease (CKD). Your child may be eligible if they have reduced kidney function and elevated protein in their urine, and are already on stable kidney treatments.
This trial tests if empagliflozin, a diabetes medicine that also protects the kidneys, can help people who have received a kidney transplant. It may be an option if you have reduced kidney function or diabetes after transplant.
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
This study looks at how SGLT2 inhibitors (a type of diabetes medication) protect the kidneys in people with type 2 diabetes and kidney disease. It may help explain why these drugs are beneficial for kidney health.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.